Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcela V Maus

Showing results (41-50 of 235) with videos related to

Pageof 24
Sort By:
Best Practice & Research. Clinical Haematology|June 19, 2018
Toxicities associated with immunotherapies for hematologic malignanciesMark B Leick, Marcela V Maus
Blood Advances|November 24, 2020
C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomasCaron A Jacobson, Marcela V Maus
Current Opinion in Immunology|March 22, 2021
Mechanisms of response and resistance to CAR T cell therapiesTrisha R Berger, Marcela V Maus
Current Opinion in Infectious Diseases|July 14, 2020
Infections associated with the new 'nibs and mabs' and cellular therapiesMarcela V Maus, Michail S Lionakis
The Journal of Clinical Investigation|January 2, 2026
Fanning the flames: IFN-γ fuels CAR-T inflammation and cytopeniaStefanie R Bailey, Marcela V Maus
Journal for Immunotherapy of Cancer|September 22, 2022
High antigen density of BCMA: friend or foe to CAR T cells?Mahmoud R Gaballa, Marcela V Maus
Oncology Research and Treatment|December 4, 2015
CD19-Targeted CAR T Cells: A New Tool in the Fight against B Cell MalignanciesBrian C Miller, Marcela V Maus
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2014
CARTs on the road for myelomaMarcela V Maus, Carl H June
Annual Review of Medicine|August 11, 2020
Toward Better Understanding and Management of CAR-T Cell-Associated ToxicityAndrea Schmidts, Marc Wehrli, Marcela V Maus
Transplantation and Cellular Therapy|March 17, 2024
National Survey of FACT-Accredited Cell Processing Facilities: Assessing Preparedness for Local Manufacturing of Immune Effector CellsMagdi Elsallab, Florence Bourgeois, Marcela V Maus
Pageof 24

Showing results (41-50 of 235) with videos related to

Sort By:
Pageof 24
Best Practice & Research. Clinical Haematology|June 19, 2018
Toxicities associated with immunotherapies for hematologic malignanciesMark B Leick, Marcela V Maus
Blood Advances|November 24, 2020
C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomasCaron A Jacobson, Marcela V Maus
Current Opinion in Immunology|March 22, 2021
Mechanisms of response and resistance to CAR T cell therapiesTrisha R Berger, Marcela V Maus
Current Opinion in Infectious Diseases|July 14, 2020
Infections associated with the new 'nibs and mabs' and cellular therapiesMarcela V Maus, Michail S Lionakis
The Journal of Clinical Investigation|January 2, 2026
Fanning the flames: IFN-γ fuels CAR-T inflammation and cytopeniaStefanie R Bailey, Marcela V Maus
Journal for Immunotherapy of Cancer|September 22, 2022
High antigen density of BCMA: friend or foe to CAR T cells?Mahmoud R Gaballa, Marcela V Maus
Oncology Research and Treatment|December 4, 2015
CD19-Targeted CAR T Cells: A New Tool in the Fight against B Cell MalignanciesBrian C Miller, Marcela V Maus
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2014
CARTs on the road for myelomaMarcela V Maus, Carl H June
Annual Review of Medicine|August 11, 2020
Toward Better Understanding and Management of CAR-T Cell-Associated ToxicityAndrea Schmidts, Marc Wehrli, Marcela V Maus
Transplantation and Cellular Therapy|March 17, 2024
National Survey of FACT-Accredited Cell Processing Facilities: Assessing Preparedness for Local Manufacturing of Immune Effector CellsMagdi Elsallab, Florence Bourgeois, Marcela V Maus
Pageof 24